Pancreatic Cancer Research

ResearcherUniversity Hospitals of ClevelandActive in the last 2 years

John Brian Ammori

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2131-0369; OpenAlex author ID A5043956301. Sources: OpenAlex.

Their work

Papers
23 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 2 papers · 2021: 6 papers · 2022: 6 papers · 2023: 3 papers · 2024: 2 papers

Papers 23

  1. Understanding surgical attrition for "resectable" pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.11.008↗
  2. To Revise or Not Revise? Isolated Margin Positivity in Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-024-15616-y↗
  3. Disparities in guideline-compliant care for patients with pancreatic ductal adenocarcinoma at minority-versus non-minority-serving hospitals. Co-author DOI 10.1016/j.hpb.2023.07.903↗
  4. An analysis of time to treatment in patients with pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2023.03.011↗
  5. Trends in and Prognostic Significance of Time to Treatment in Pancreatic Cancer: A Population-Based Study. Co-author DOI 10.1245/s10434-023-14221-9↗
  6. Weight loss during neoadjuvant therapy for pancreatic cancer does not predict poor outcomes. Co-author DOI 10.1016/j.amjsurg.2021.10.001↗
  7. Combined multiagent chemotherapy and radiotherapy is associated with prolonged overall survival in patients with non-operatively managed stage II-III pancreati… Co-author DOI 10.1016/j.hpb.2021.08.938↗
  8. Multimodal therapy with or without irreversible electroporation for unresectable locally advanced pancreatic adenocarcinoma: a systematic review and meta-analy… Co-author DOI 10.1016/j.hpb.2021.12.014↗
  9. Average treatment effect of facility hepatopancreatobiliary cancer volume on survival of non-resected pancreatic adenocarcinoma. Co-author DOI 10.1016/j.hpb.2022.07.007↗
  10. Time to Neoadjuvant Chemotherapy Initiation Is not Associated With Survival in Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2022.03.013↗
  11. A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Co-author DOI 10.1016/j.surg.2021.10.023↗
  12. The importance of time-to-adjuvant treatment on survival with pancreatic cancer: A systematic review and meta-analysis. Co-author DOI 10.1002/cnr2.1390↗
  13. Neoadjuvant chemoradiation may be associated with improved pathologic response in pancreatic cancer. Co-author DOI 10.1016/j.amjsurg.2020.11.035↗
  14. Facility volume-survival relationship in patients with early-stage pancreatic adenocarcinoma treated with neoadjuvant chemotherapy followed by pancreatoduodene… Co-author DOI 10.1016/j.surg.2020.12.003↗
  15. Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1089/pancan.2021.0003↗
  16. Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagen… Co-author DOI 10.1177/00031348211038581↗
  17. Elucidating the Causes of Improved Survival in Clinical Trials of Randomized Adjuvant Pancreatic Ductal Adenocarcinoma (PDAC). Co-author DOI 10.1245/s10434-020-08859-y↗
  18. Neoadjuvant chemotherapy is associated with improved survival in patients with left-sided pancreatic adenocarcinoma. Co-author DOI 10.1002/jso.26196↗
  19. A comprehensive analysis of clinical trials in pancreatic cancer: what is coming down the pike? Co-author DOI 10.18632/oncotarget.27727↗
  20. Pretherapy neutrophil to lymphocyte ratio and platelet to lymphocyte ratio do not predict survival in resectable pancreatic cancer. Last author DOI 10.1016/j.hpb.2017.10.011↗
  21. Surgery for Localized Pancreatic Cancer: The Trend Is Not Improving. Co-author DOI 10.1097/mpa.0000000000000511↗
  22. The role of neoadjuvant therapy in pancreatic cancer: a review. First author DOI 10.2217/fon.15.335↗
  23. Trends in the treatment of resectable pancreatic adenocarcinoma. First author DOI 10.1007/s11605-013-2335-x↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jeffrey M. Hardacre · 22 shared papers, 2014–2024 · strength 3.16
  2. Jordan Michael Winter · 18 shared papers, 2020–2024 · strength 2.72
  3. Lee Mayer Ocuin · 17 shared papers, 2020–2024 · strength 2.62
  4. Jonathan J. Hue · 15 shared papers, 2020–2024 · strength 2.27
  5. Luke Daniel Rothermel · 13 shared papers, 2020–2023 · strength 1.90
  6. Kavin Sugumar · 12 shared papers, 2021–2023 · strength 1.82
  7. Mohamedraed Elshami · 7 shared papers, 2022–2024 · strength 1.22
  8. David Lawrence Bajor · 7 shared papers, 2020–2023 · strength 0.95
  9. Sarah Coseo Markt · 4 shared papers, 2021–2022 · strength 0.56
  10. Richard S. Hoehn · 3 shared papers, 2022–2024 · strength 0.53
  11. Shreya Gupta · 2 shared papers, 2023 · strength 0.36
  12. Hanna H. Kakish · 2 shared papers, 2022–2024 · strength 0.35
  13. Jennifer Anne Dorth · 3 shared papers, 2016–2022 · strength 0.35
  14. Erryk Katayama · 2 shared papers, 2020–2022 · strength 0.26
  15. Sakti Chakrabarti · 1 shared paper, 2023 · strength 0.17
  16. Amit Mahipal · 1 shared paper, 2023 · strength 0.17
  17. Andre Alabd · 1 shared paper, 2021 · strength 0.15
  18. Siavash Raigani · 2 shared papers, 2014–2016 · strength 0.14
  19. Shaffer R. S. Mok · 1 shared paper, 2022 · strength 0.13
  20. Akhil Chawla · 1 shared paper, 2018 · strength 0.10
  21. Jennifer Rachel Eads · 1 shared paper, 2016 · strength 0.08
  22. Suzanne M. Russo · 1 shared paper, 2016 · strength 0.08
  23. Julian A. Kim · 1 shared paper, 2016 · strength 0.08
  24. Madeleine P. Strohl · 1 shared paper, 2016 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.